268 related articles for article (PubMed ID: 1634229)
1. Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.
Schmid B; Paton BC; Sandhoff K; Harzer K
Hum Genet; 1992 Jul; 89(5):513-8. PubMed ID: 1634229
[TBL] [Abstract][Full Text] [Related]
2. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.
Bradová V; Smíd F; Ulrich-Bott B; Roggendorf W; Paton BC; Harzer K
Hum Genet; 1993 Sep; 92(2):143-52. PubMed ID: 8370580
[TBL] [Abstract][Full Text] [Related]
3. Degradation of membrane-bound ganglioside GM1. Stimulation by bis(monoacylglycero)phosphate and the activator proteins SAP-B and GM2-AP.
Wilkening G; Linke T; Uhlhorn-Dierks G; Sandhoff K
J Biol Chem; 2000 Nov; 275(46):35814-9. PubMed ID: 10942779
[TBL] [Abstract][Full Text] [Related]
4. Saposins (sap) A and C activate the degradation of galactosylceramide in living cells.
Harzer K; Paton BC; Christomanou H; Chatelut M; Levade T; Hiraiwa M; O'Brien JS
FEBS Lett; 1997 Nov; 417(3):270-4. PubMed ID: 9409731
[TBL] [Abstract][Full Text] [Related]
5. Physiological relevance of sphingolipid activator proteins in cultured human fibroblasts.
Sadeghlar F; Remmel N; Breiden B; Klingenstein R; Schwarzmann G; Sandhoff K
Biochimie; 2003; 85(3-4):439-48. PubMed ID: 12770782
[TBL] [Abstract][Full Text] [Related]
6. Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase.
Paton BC; Schmid B; Kustermann-Kuhn B; Poulos A; Harzer K
Biochem J; 1992 Jul; 285 ( Pt 2)(Pt 2):481-8. PubMed ID: 1637339
[TBL] [Abstract][Full Text] [Related]
7. Uptake and metabolism of radiolabelled GM1-ganglioside in skin fibroblasts from controls and patients with GM1-gangliosidosis.
Midorikawa M; Inui K; Okada S; Yabuuchi H; Ogura K; Handa S
J Inherit Metab Dis; 1991; 14(5):721-9. PubMed ID: 1779618
[TBL] [Abstract][Full Text] [Related]
8. Further evidence that human lysosomal sialidase is not derived from prosaposin. Prosaposin biosynthesis and ganglioside sialidase studies in prosaposin- and sialidase-deficient fibroblast lines.
Paton BC; Schneider-Jakob HR; Kopitz J; Harzer K; Poulos A; Cantz M
Biol Chem Hoppe Seyler; 1994 Jan; 375(1):25-9. PubMed ID: 8003252
[TBL] [Abstract][Full Text] [Related]
9. Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies.
Chatelut M; Harzer K; Christomanou H; Feunteun J; Pieraggi MT; Paton BC; Kishimoto Y; O'Brien JS; Basile JP; Thiers JC; Salvayre R; Levade T
Clin Chim Acta; 1997 Jun; 262(1-2):61-76. PubMed ID: 9204210
[TBL] [Abstract][Full Text] [Related]
10. Biosynthesis of the sulfatide/GM1 activator protein (SAP-1) in control and mutant cultured skin fibroblasts.
Fujibayashi S; Wenger DA
Biochim Biophys Acta; 1986 Feb; 875(3):554-62. PubMed ID: 3081038
[TBL] [Abstract][Full Text] [Related]
11. GM1-gangliosidosis: accumulation of ganglioside GM1 in cultured skin fibroblasts and correlation with clinical types.
Suzuki Y; Nakamura N; Fukuoka K
Hum Genet; 1978 Aug; 43(2):127-31. PubMed ID: 99363
[TBL] [Abstract][Full Text] [Related]
12. Biochemical, immunological, and structural studies on a sphingolipid activator protein (SAP-1).
Inui K; Wenger DA
Arch Biochem Biophys; 1984 Sep; 233(2):556-64. PubMed ID: 6435528
[TBL] [Abstract][Full Text] [Related]
13. [Disorders of sphingolipid activator proteins].
Suzuki Y
Nihon Rinsho; 1995 Dec; 53(12):3025-7. PubMed ID: 8577053
[TBL] [Abstract][Full Text] [Related]
14. [The metabolism of radiolabelled GM1-ganglioside in cultured skin fibroblasts from controls and patients with GM1-gangliosidosis].
Inui K
Nihon Rinsho; 1995 Dec; 53(12):3102-4. PubMed ID: 8577066
[TBL] [Abstract][Full Text] [Related]
15. Modulation of human saposin B sphingolipid-binding specificity by alternative splicing. A study with saposin B-derived synthetic peptides.
Lamontagne S; Potier M
J Biol Chem; 1994 Aug; 269(32):20528-32. PubMed ID: 8051151
[TBL] [Abstract][Full Text] [Related]
16. Binding of GM1 ganglioside to a synthetic peptide derived from the lysosomal sphingolipid activator protein saposin B.
Champagne MJ; Lamontagne S; Potier M
FEBS Lett; 1994 Aug; 349(3):439-41. PubMed ID: 8050611
[TBL] [Abstract][Full Text] [Related]
17. Binding of GM1-ganglioside to a synthetic peptide derived from the lysosomal sphingolipid-activator-protein saposin B.
Champagne MJ; Lamontagne S; Potier M
FEBS Lett; 1994 Jun; 347(2-3):265-7. PubMed ID: 8034015
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of sphingolipids in SAP-precursor (prosaposin)-deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor.
Burkhardt JK; Hüttler S; Klein A; Möbius W; Habermann A; Griffiths G; Sandhoff K
Eur J Cell Biol; 1997 May; 73(1):10-8. PubMed ID: 9174667
[TBL] [Abstract][Full Text] [Related]
19. High-resolution loading tests in the study of genetic heterogeneity in gangliosidosis fibroblasts.
Akhunov VS; Mirenburg TV; Krasnopolskaya XD
J Inherit Metab Dis; 1994; 17(1):104-11. PubMed ID: 8051915
[TBL] [Abstract][Full Text] [Related]
20. Incorporation and metabolism of ganglioside GM2 in skin fibroblasts from normal and GM2 gangliosidosis subjects.
Sonderfeld S; Conzelmann E; Schwarzmann G; Burg J; Hinrichs U; Sandhoff K
Eur J Biochem; 1985 Jun; 149(2):247-55. PubMed ID: 3922757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
